NCT07407205Active, not recruiting
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and Magnetic Resonance Perfusion in Predicting Response to Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Carcinoma and Disease Course After Treatment
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
This prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance (MR) perfusion imaging in patients with HPV-negative oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy. The aim is to improve prediction of treatment response and disease course after treatment, support decision-making regarding optimal therapy, and potentially reduce the number of imaging examinations required during follow-up.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 6 Feb 2026
- Start date
- 10 Jun 2019
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Head and neck cancer
- NCT number
- NCT07407205
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 10 Jun 2019 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- HPV-positive oropharyngeal carcinoma
- Contraindications for MRI
- Severe comorbidities preventing chemoradiotherapy
- Pregnancy or breastfeeding
- Inability to comply with study procedures
Who the study is looking for
- Age ≥ 18 years
- Histologically confirmed HPV-negative oropharyngeal squamous cell carcinoma
- Planned treatment with concurrent chemoradiotherapy
- Ability to undergo MRI examination
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.